«Biomedicine of Cardiovascular Diseases. Translational Pharmacology and Innovations in Therapy» - such is the title of the conference that was opened at Kazan University on November 25th.

The event is co-organized by KFU, Pfizer and Future Biotech.

Cardiovascular diseases account to 55 percent of deaths in developed countries (including Russia). The leaders in this grim competition are ischemia (46.8 percent of all CVD deaths) and strokes (38.7 percent). In Russia the situation is especially dire. In the 45 – 74 age group CVD deaths amount to 1 343 per 100 thousand for men and 657 per 100 thousand for women. In  France, for example, these numbers are only 330 and 122 respectively.

CVDs are the main cause of death in Russia, as is the case with the rest of the world. The aggravating factors are late visits to qualified physicians, bad organization of medical help and unsatisfactory patients' discipline. The result is very regrettable – in January-March 2015 CVD deaths rose 5.2 percent year-to-year in Russia. In Europe the numbers are falling.

This shows that qualified cardiologists are in big demand in Russian medical community. Tatarstan is a good example among Russian regions. As Deputy Minister of Healthcare of Tatarstan Sergey Osipov said, the Republic has a network of cardiovascular centers and a good organization of self-exam and preventive help at medical facilities and workplaces.

CVD deaths fell 0.5 percent year-to-year in Tatarstan in 2015. Deputy Minister added that Tatarstan has the lowest number of CVD deaths in the Volga Federal District. He also said that only 15 percent of success in battling such diseases depends on medical help, the rest is healthy nutrition, abstinence from smoking and physical exercise.

This is what Director of Corporate Programs at Pfizer Yelena Mukhachyova had to say, “Our goal in Russia is to provide high-quality modern medications to the populace. We understand that investment is not by itself sufficient for the progress of pharmaceutical industry – we also need qualified experts who move the industry and the science forward. National scientific potential development and staff training is also necessary. This conference allows young researchers to discuss pertinent problems of CVD treatment and newest developments in this field, it also helps the progress of Russian biomedicine”.

Director of the Institute of Fundamental Medicine and Biology Andrey Kiyasov presented his report on translational medicine. Its high effectiveness is determined by high-tech developments and interdisciplinary approach – translational medicine unites bioinformatics, genomics, molecular biology, and other areas.

The three-day conference consists of expert panels, discussions about the latest fundamental research and treatment methods. Among the topics are “Pertinence of CVDs and newest methods of research and treatment”, “Translational research in cardiology”, “New methods of treating cardiac insufficiency”, “Distant monitoring of treatment processes”, and “Epidemiology of the risk factors of CVDs”. There is also a medical adventure game planned for young scientists – it will take place at the Medical Simulation Center.